Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors

Plain-language summary

This study examined the effect of the herbal product HepatoKeeper (Ganwei) compared with Metformin and placebo in people with non-alcoholic fatty liver disease. It enrolled adults aged 20-80 with a suspected or confirmed diagnosis of fatty liver. The study did not use a phase designation and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Taipei City Hospital

Intervention

Ganwei, Metformin, Placebo

Start date

9/22/2021

Estimated completion

6/13/2023

Countries

Taiwan

Related genes

Locations

• Taipei, Taiwan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Must be willing to participate in the study and provide written informed consent.
* Male and female adults ≥20 and \<80 years of age.
* Suspected or confirmed diagnosis of NAFLD:

  * Fibroscan with CAP ≥220 dB/m
  * Criteria for diagnosing fatty liver: Abdominal ultrasound reveals differences in liver and kidney parenchyma due to wave reflection, liver parenchymal ultrasound attenuation, and blurred imaging of liver vessels and diaphragm, indicating fatty liver.

Exclusion Criteria:

* Female patients who are pregnant or breastfeeding.
* Diabetic patients undergoing medication treatment.
* Patients clinically diagnosed with alcoholic hepatitis, autoimmune hepatitis, or biliary liver disease.
* Excessive alcohol consumption (more than 15 grams/day for females, more than 30 grams/day for males).
* Users of weight-loss products and vitamin E supplements.
* Individuals with an estimated Glomerular Filtration Rate (eGFR) less than 60 mL/min/1.73m².